<PAGE>
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTER ENDED MAY 31, 1997
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________
TO _________
Commission File Number: 0-11868
CARDIODYNAMICS INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S><C>
CALIFORNIA 95-3533362
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
6155 CORNERSTONE COURT EAST, SUITE 125, SAN DIEGO, CALIFORNIA 92121
(Address of principal executive offices) (Zip Code)
</TABLE>
(619) 535-0202
(Registrant's telephone number)
Check whether the registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes X No
---- ---
Check whether the registrant has filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court.
Yes X No
---- ----
As of July 1, 1997, 31,872,628 shares of Common Stock were outstanding.
Transitional Small Business Disclosure Format
(check one):
Yes No X
---- ----
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
FORM 10-QSB
TABLE OF CONTENTS
PAGE NO.
--------
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS:
Condensed Balance Sheets at May 31, 1997,
(UNAUDITED) and November 30, 1996, (AUDITED). 3
Condensed Statements of Operations, (UNAUDITED) for
the three and six month periods ended May 31, 1997
and May 31, 1996. 5
Condensed Statements of Cash Flows, (UNAUDITED) for
the six months ended May 31, 1997 and May 31, 1996. 6
Notes to Condensed Financial Statements, (UNAUDITED) 7
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION 8
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS 10
ITEM 2. CHANGES IN SECURITIES 10
ITEM 3. DEFAULTS UPON SENIOR SECURITIES 10
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS 10
ITEM 5. OTHER INFORMATION 10
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K 10
SIGNATURES 11
2
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CARDIODYNAMICS INTERNATIONAL CORPORATION
CONDENSED BALANCE SHEETS
<TABLE>
<CAPTION>
MAY 31, NOVEMBER 30,
1997 1996
ASSETS (Unaudited) (Audited)
----------- ------------
<S> <C> <C>
Current assets:
Cash and cash equivalents $4,701,109 $706,190
Marketable securities -- 262,619
Receivables, less allowance for doubtful receivables
of $5,632 and $7,461, respectively 546,841 24,925
Inventory, net 690,989 293,629
Other current assets 10,166 68,336
---------- ---------
Total current assets 5,949,105 1,355,699
Property and equipment, at cost 349,508 265,781
Less accumulated depreciation 179,426 156,149
---------- ---------
Net property and equipment 170,082 109,632
Other assets:
Deposits 6,502 4,250
---------- ---------
Total assets $6,125,689 $1,469,581
---------- ---------
---------- ---------
</TABLE>
See accompanying notes to condensed financial statements
3
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
CONDENSED BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
MAY 31, NOVEMBER 30,
1997 1996
LIABILITIES AND SHAREHOLDERS' EQUITY (Unaudited) (Audited)
----------- ------------
<S> <C> <C>
Current liabilities:
Accounts payable $301,697 $125,385
Accrued salaries, wages and related benefits 51,877 28,882
Other accrued expenses 16,113 67,264
Customer deposits -- 23,012
Marketable securities held for redeemed preferred shares -- 22,676
Current portion of long-term debt 12,100 12,100
---------- ---------
Total current liabilities 381,787 279,319
Long-term debt, less current maturities 31,363 37,822
Commitments and contingencies
Shareholders' equity:
Preferred stock, no par, 500,000 shares authorized;
issued and outstanding 183,115 in May and
November, respectively. 457,791 457,791
Common stock, no par, 50,000,000 shares authorized;
issued and outstanding 31,872,628 shares in
May and 29,581,696 in November 14,323,569 8,366,514
Unrealized loss on marketable securities -- (89,270)
Accumulated deficit (9,068,821) (7,582,595)
---------- ---------
Total shareholders' equity 5,712,539 1,152,440
---------- ---------
Total liabilities and shareholders' equity $6,125,689 $1,469,581
---------- ---------
---------- ---------
</TABLE>
See accompanying notes to condensed financial statements
4
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
THREE MONTHS ENDED SIX MONTHS ENDED
MAY 31, MAY 31,
-------------------------- ------------------------
1997 1996 1997 1996
--------- --------- --------- --------
<S> <C> <C> <C> <C>
Net sales $778,528 $11,771 $910,456 $72,716
Cost of sales 367,420 32,052 461,602 64,783
---------- ---------- ----------- ----------
Gross margin 411,108 (20,281) 448,854 7,933
Operating expenses:
Selling, general and
administrative expenses 754,097 480,153 1,441,127 744,187
Research and development 231,619 159,832 403,996 233,192
---------- ---------- ----------- ----------
Total operating expenses 985,716 639,985 1,845,123 977,379
Loss from operations (574,608) (660,266) (1,396,269) (969,446)
Other income (expense):
Interest, net 71,746 (4,715) 75,696 (4,892)
Loss on disposition of
marketable securities -- -- (164,853) --
Other income -- 693 -- 693
---------- ---------- ----------- ----------
Total other income (expense) 71,746 (4,022) (89,157) (4,199)
Loss before provision for
income taxes (502,862) (664,288) (1,485,426) (973,645)
Provision for income taxes -- -- (800) (800)
---------- ---------- ----------- ----------
Net loss ($502,862) ($664,288) ($1,486,226) ($974,445)
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
Net loss per common share ($0.02) ($0.04) ($0.05) ($0.05)
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
Weighted average number
of common and common
equivalent shares outstanding 31,865,439 18,019,781 30,771,712 17,985,949
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
</TABLE>
See accompanying notes to condensed financial statements
5
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
SIX MONTHS ENDED MAY 31,
---------------------------
CASH FLOWS FROM OPERATING ACTIVITIES: 1997 1996
-------------- ----------
<S> <C> <C>
Net loss ($1,486,226) ($974,445)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation 23,277 21,987
Loss on disposition of marketable securities 164,853 --
Changes in operating assets and liabilities:
Receivables (521,916) 65,075
Inventories (397,360) (125,126)
Other current assets 58,170 (1,958)
Deposits (2,252) 2,365
Accounts payable 176,312 (101,464)
Accrued salaries, wages and related benefits 22,995 (26,051)
Other accrued expenses (51,151) (80,476)
Customer deposits (23,012) (13,025)
--------- ---------
Net cash used in operating activities (2,036,310) (1,233,118)
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of marketable securities 180,129 --
Purchase of property and equipment (83,727) (20,724)
--------- ---------
Net cash provided by/(used in) investing activities 96,402 (20,724)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of long-term debt (6,459) (17,451)
Increase in long-term debt -- 625,000
Proceeds from exercise of warrants 200 226
Cash payment for redeemed preferred shares (15,769) --
Issuance of common stock 5,956,855 698,250
--------- ---------
Net cash provided by financing activities 5,934,827 1,306,025
--------- ---------
Net increase in cash and cash equivalents 3,994,919 52,183
Cash and cash equivalents at beginning of period 706,190 7,441
--------- ---------
Cash and cash equivalents at end of period $4,701,109 $59,624
--------- ---------
--------- ---------
</TABLE>
See accompanying notes to condensed financial statements
6
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
DESCRIPTION OF BUSINESS:
CardioDynamics International Corporation develops, manufactures and markets
noninvasive digital heart monitoring devices which provide continuous data on a
wide range of hemodynamic parameters (measurements of the heart's ability to
deliver oxygen-rich blood throughout the body). The Company's primary product,
the BioZ-TM- System, uses Thoracic Electrical Bioimpedance (TEB) technology to
obtain data which is typically available only through a time consuming, costly,
potentially dangerous invasive procedure called right-heart catheterization
(RHC). Since TEB monitoring is noninvasive, it eliminates patient risk and
potentially decreases the length of a hospital stay, thereby reducing patient
cost.
BASIS OF PRESENTATION:
The accompanying condensed financial statements have been prepared in accordance
with the requirements for Form 10-QSB and therefore do not include all
information and footnotes which would be presented were such financial
statements prepared in accordance with generally accepted accounting principles.
These statements should be read in conjunction with the Company's November 30,
1996 audited financial statements and notes thereto as presented in its Annual
Report on Form 10-KSB. Financial presentations for the prior periods have been
reclassified to conform with the current presentation.
In the opinion of management, the information contained herein reflects all
adjustments necessary to make the results of operations for the interim periods
a fair statement of such operations. All such adjustments are of a normal
recurring nature. The results of operations for the six months ended May 31,
1997 are not necessarily indicative of the results that may be expected for the
full fiscal year ended November 30, 1997.
7
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
PART I - FINANCIAL INFORMATION, (CONTINUED)
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
The following discussion should be read in conjunction with the condensed
financial statements and notes thereto included in Item 1 of this report, and
with the Company's audited financial statements and notes thereto for the fiscal
year ended November 30, 1996.
RESULTS OF OPERATIONS
Sales for the second fiscal quarter of 1997 increased to $778,528 from $11,771
in the second fiscal quarter of 1996. Sales for the six months ended May 31,
1997 increased to $910,456 from $72,716 for the same six-month period in 1996.
The significant increase in sales during the second fiscal quarter of 1997 was
due to the commencement of volume shipments of its new BioZ-TM- System primarily
to its network of specialty distributors for demonstration and stocking units.
Sales in the comparable period of 1996 were of a prior product line.
The Company received 510(k) marketing clearance for the BioZ-TM- System in late
November 1996. This provides the Company the opportunity to commercialize the
BioZ-TM- System, which could result in significantly increased sales.
The gross margin as a percent of net sales for the quarter ended May 31, 1997
was 53%, compared with a negative gross margin for the same quarter in fiscal
1996. The significant improvement is due to the increased sales volume in the
quarter relative to the Company's manufacturing and related overhead costs.
Selling, general and administrative costs in the second quarter of fiscal 1997
were approximately $274,000 and $697,000 higher than in the second quarter and
first half of fiscal 1996 respectively, primarily due to the addition of
regional sales managers, costs related to establishing a network of specialty
distributors, development of advertising and marketing materials, and
strengthening of the management team.
The Company continues to invest in additional engineering and clinical
personnel to support further enhancements to the BioZ-TM- System and new
product development. As a result, research and development expenses increased
by approximately $72,000 or 45% in the second quarter of fiscal 1997 over last
year's same quarter, and by approximately $171,000 or 73% in the first six
months of fiscal 1997 over last year's first six months.
In the first quarter of 1997, the Company recognized a loss of $164,853 related
to the disposition of certain marketable securities. These securities had been
held for payment to preferred shareholders upon exercise of a right to redeem
their preferred shares for common stock and a pro-rata portion of the proceeds
of the marketable securities. Because the time for exercising the redemption
right had expired, the Company sold the securities to free up cash for operating
activities.
8
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION, (CONTINUED)
In accordance with Statement of Financial Accounting Standards No. 115,
Accounting for Certain Investments in Debt and Equity Securities, the Company
had earlier classified the investment securities as "available-for-sale."
Accordingly, unrealized gains and losses were excluded from earnings and
reported as a separate component of shareholders' equity until sold. The
realized loss was computed based on specific identification of the securities
sold or written-off. At November 30, 1996, the Company accrued $22,676 for
payment to preferred shareholders who exercised their conversion right which
ended in April 1996. The actual amount paid to these preferred shareholders,
based on the net proceeds of the sale of those securities, was $15,769.
The Company incurred a net loss for the second quarter of 1997 of $.02 per
common share compared with a net loss of $.04 per common share in the same
quarter last year. The weighted average number of common shares outstanding for
the second quarter of 1997 was 31,865,439, versus 18,019,781 reported in the
second quarter of 1996. The Company incurred a net loss of $1,486,226 versus a
net loss of $973,645 for the six months ended May 31, 1997 and 1996
respectively. The increased number of outstanding shares was primarily due to
an affiliate's conversion of the principal amount of a convertible Note into 7.2
million shares in June 1996 and the issuance of approximately 2.5 million shares
in a private placement through EVEREN Securities, Inc., in February and March
1997 (described below).
LIQUIDITY AND CAPITAL RESOURCES
To fund the Company's BioZ-TM- product commercialization, ongoing research and
development efforts, marketing programs, capital expenditures and working
capital requirements, the Company raised approximately $7.2 million in a private
placement of approximately 2.5 million shares of common stock through EVEREN
Securities, Inc. The initial $6.2 million was funded at the end of the first
fiscal quarter of 1997 with the balance completed in early March 1997.
As a result of the private placement, the overall cash balance increased by
$3,994,919 in the six months ended May 31, 1997 and working capital increased to
$5,567,318, up from $1,076,380 at November 30, 1996. The Company has been using
cash to ramp up its commercial activities. For example, receivables increased
by $521,916 in the first six months of fiscal 1997 due to commencement of
initial volume shipments of the BioZ-TM- System and $397,360 of operating cash
was used to begin building inventories in anticipation of future sales.
The Company believes that it has sufficient financial resources to support its
forecasted working capital and capital expenditure requirements for the balance
of 1997 with cash on hand. Longer term, the Company's liquidity will depend on
its ability to successfully commercialize the BioZ-TM- System and other
diagnostic products.
9
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 2. CHANGES IN SECURITIES
On March 6, 1997 the Company completed a $7.2 million placement of
approximately 2.5 million shares of its common stock in a private
placement to institutional and accredited investors. EVEREN
Securities, Inc. acted as the placement agent for which they received
a fee of approximately $461,000.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5. OTHER INFORMATION
In June 1997 the Company announced the appointments of Rhonda Pederson
as President, formerly the Company's Chief operating officer, and
Richard Trayler as Chief Operating Officer. Richard Otto, who
previously held the title of President and CEO will remain as the
Company's Chief Executive Officer.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
10.1 Distribution Agreement, dated March 27, 1997, between the Company
and Kol Bio Medical Instruments, Inc.
27 Financial Data Schedule.
(b) Reports on Form 8-K:
No reports on Form 8-K were filed during the quarter ended May 31,
1997.
10
<PAGE>
CARDIODYNAMICS INTERNATIONAL CORPORATION
THIS DOCUMENT'S "FORWARD-LOOKING" STATEMENTS (THOSE NOT LIMITED TO HISTORICAL
INFORMATION) INHERENTLY INVOLVE RISKS AND UNCERTAINTIES. AMONG THE FACTORS THAT
COULD CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE
INDICATED IN ANY SUCH FORWARD-LOOKING STATEMENTS ARE: (i) SOLE DEPENDENCE ON THE
NEWLY-INTRODUCED BIOZ-TM- SYSTEM AND RELATED PRODUCTS, (ii) GENERAL ACCEPTANCE
IN THE MEDICAL COMMUNITY OF INVASIVE PROCEDURES SUCH AS RHC AND LACK OF GENERAL
ACCEPTANCE IN THE MEDICAL COMMUNITY OF THORACIC ELECTRICAL BIOIMPEDANCE (TEB),
(iii) THE TIMING AND RESULTS OF MULTI-CENTER AND OTHER CLINICAL TRIALS OF THE
BIOZ-TM- SYSTEM, (iv) COMPETITION FROM BAXTER HEALTHCARE CORPORATION, THE MAKER
OF THE SWAN-GANZ-TM- RHC DEVICE, AND (v) VARIOUS UNCERTAINTIES CHARACTERISTIC OF
COMPANIES JUST EMERGING FROM THE DEVELOPMENT STAGE; AS WELL AS OTHER RISKS
DETAILED IN THE COMPANY'S ANNUAL REPORT ON FORM 10-KSB FOR THE FISCAL YEAR ENDED
NOVEMBER 30, 1996 AND ANY LATER-FILED SEC REPORTS. THE COMPANY DOES NOT
UNDERTAKE TO UPDATE THE DISCLOSURES CONTAINED IN THIS DOCUMENT.
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
CARDIODYNAMICS INTERNATIONAL CORPORATION
Date: July 14, 1997 By: /s/ Richard E. Otto
------------------------ ----------------------
Richard E. Otto
Chief Executive Officer
Date: July 14, 1997 By: /S/ Stephen P. Loomis
------------------------- -----------------------
Stephen P. Loomis
Vice President, Finance
Chief Financial Officer
11
<PAGE>
AMENDED AND RESTATED
DISTRIBUTION AGREEMENT
This Distribution Agreement (the "Agreement") is entered as of March 27,
1997 by and between CardioDynamics International Corporation ("Supplier"), a
California corporation, with its registered office and/or place where business
is actually carried out at 6155 Cornerstone Court East, Suite 125; San Diego,
California; and Kol Bio Medical Instruments, Inc. ("Distributor"), a Virginia
corporation, with its registered office and/or place where business is actually
carried out at 13901 Willard Road; Chantilly, Virginia.
1. APPOINTMENT; TERRITORY; PRODUCTS. Supplier hereby appoints
Distributor for the term of this Agreement as, and Distributor agrees to act as,
Supplier's exclusive hospital distributor of the Products (as hereinafter
defined) for the Territory specified in Attachment A, subject to all the terms
and conditions hereof. The Distributor will have the right to sell to hospital
accounts within their assigned Territory. A hospital account is one that is
listed in the American Hospital Association's (AHA's) Annual Guide. So long
during the term of this Agreement as Distributor remains in full compliance with
this Agreement, Supplier will not appoint another hospital distributor for the
Products in the Territory. Distributor shall refrain from establishing or
maintaining any branch, warehouse or distribution depot for the Products outside
the Territory, and shall not engage in any advertising or promotional activities
relating to the Products directed primarily to customers located outside the
authorized market or authorized Territory. Furthermore, Distributor may only
sell its Product to end users and may not sell to other Distributors for the
purpose of reselling to end-users unless the Distributor has express written
consent of the Director of Sales of the Supplier. "Product" shall mean the
selected Supplier products which are expressly set forth in Attachment B. Any
enhancement or improvement of a Product that is made generally available by
Supplier, that is substantially similar to such Product, and that is marketed
under the same product number and nomenclature as such Product shall be added to
Attachment B as a Product. Supplier reserves the right to change, modify or
discontinue any Product at any time. Supplier may add Products to Attachment B
and may remove any discontinued Product therefrom.
2. PAYMENT AND SUPPLY TERMS.
a. Products are delivered F.O.B. Supplier's applicable warehouse or
place of production. Purchase prices payable by Distributor are Supplier's then
current hospital distributor wholesale price list. Supplier shall have the
right, in its sole discretion, from time to time or at any time, to change such
list prices with ninety (90) days written notice. New prices will apply to all
shipments made after such notice period. In addition, Distributor will pay all
charges including, without limitation, freight, shipping, customs charges and
expenses, cost of special packaging or handling, and insurance premiums, and
shall be responsible for all taxes, including, but not limited to, sales, value
added and use taxes, duties and other governmental assessments. Payment shall
be made in U.S. dollars and will be payable net 30.
b. During the term of this Agreement:
i. Supplier shall provide Distributor, at a Supplier's expense,
with samples of any applicable printed marketing materials that Supplier may, in
its discretion, produce for the Products.
ii. Subject to the other terms and conditions of this Agreement,
Supplier shall use its reasonable efforts to promptly fill Distributor's written
purchase orders for Products with a requested delivery date not less than sixty
(60) days after the date the purchase order is received by
1
<PAGE>
Supplier. Should Supplier fail to supply Distributor with the stocking
inventory Products ordered, the sales quotas for such period shall be reduced
dollar-for-dollar to the extent of the shortfall.
iii. Supplier will provide Distributor with, and Distributor will
accept, such training as Supplier deems appropriate at locations specified by
mutual agreement of both Supplier and Distributor; each party will bear its own
expense in connection with such training.
c. Product will be deemed accepted if not rejected by written notice
and returned to Supplier in accordance with the warranty return procedure
(Section 7) within thirty (30) days of delivery.
3. LICENSE, TRADEMARKS AND TRADE NAMES.
a. The Distributor shall not use Supplier's name or any other
trademark or trade name used or claimed by Supplier (all of which names or marks
shall hereinafter be referred to as the "Marks") in connection with any business
conducted by the Distributor other than dealing with the Products.
b. Supplier hereby grants to the Distributor a royalty free, non-
exclusive license to use the Marks, but only with respect to the sales of the
Products during the term of this Agreement.
c. Distributor shall include and shall not alter, obscure or remove
any Marks, or any markings, colors or other insignia which are contained on or
in or affixed to Products at the time of shipment.
d. Any advertising or promotional literature or announcement to the
press by Distributor regarding its relationship with Supplier or otherwise
utilizing Marks must be approved by Supplier in advance in writing.
e. Distributor agrees that it will not use, without Supplier's prior
written consent, any mark which is likely to be similar to or confused with the
Marks.
f. Distributor agrees that it has not registered, and will not
register the name "CardioDynamics International Corporation," "CDIc," "BioZ," or
any forms thereof for use in connection with any business entity without the
prior written approval of Supplier. Distributor also agrees not to use or
contest during or after the term of this Agreement any name, mark or designation
used by Supplier anywhere in the world (or any name, mark or designation similar
thereto).
g. The Distributor agrees that its use of the Marks shall not create
in its favor any right, title or interest therein and acknowledges Supplier's
exclusive right, title and interest in the Marks.
h. The Distributor hereby acknowledges and agrees that any and all
rights, title and interest in any and all trademarks and other proprietary
rights that are related in any way to the production, manufacture or sale of the
Products, or form the basis for the development of the Products are owned
solely and exclusively by Supplier, and Supplier may, in its discretion, seek to
secure and maintain any such rights. In the event that Supplier seeks to secure
or maintain or initiate any infringement action regarding such rights, the
Distributor agrees to cooperate with Supplier in any way reasonably requested.
4. DISTRIBUTOR COVENANTS AND REPRESENTATIONS. Except as expressly and
unambiguously provided herein, Distributor represents, warrants, covenants and
agrees:
a. To use its best efforts to successfully market (including,
without limitation, conducting periodic promotions, when Supplier offers
promotional programs, and conduct market research, maintaining a well staffed
salesforce and adequate inventory, and prompt inclusion of the Products in all
applicable trade shows and in Distributor's catalogs and other promotional
materials), distribute and support (including training and other support) the
Products on a continuing basis and
2
<PAGE>
to comply with good business practices and all laws and regulations relevant to
this Agreement or the subject matter hereof. In its distribution efforts,
Distributor will use Marks (but will not represent or imply that it is Supplier
or is a part of Supplier). However, all advertisements, promotional materials,
packaging and anything else bearing a Mark shall identify Supplier as the Mark
owner and Product manufacturer and shall be subject to prior written approval of
Supplier, which approval shall not be unreasonably withheld. Present salesforce
being acceptable to Supplier. Supplier will also allow Distributor to
subcontract to a qualified sub rep, sales responsibilities of some of its
Territory to better cover said Territory with a sales presence, if so deemed by
Distributor, and with the mutual approval of Supplier.
b. To keep Supplier informed of relevant market trends, customer
needs, competitive activity, economic and regulatory conditions and
Distributor's sales and inventory by Product. Distributor will also provide
Supplier with a written quarterly report with respect to these matters, if
requested by Supplier. Additionally, if requested, Distributor will also
provide Supplier with a written monthly sales tracing report.
c. That it does not currently represent or promote any lines or
products that compete with the Products.
d. That Distributor will conduct its business in a manner that
reflects favorably on the Products and shall not, without Supplier's prior
written consent, represent, promote or otherwise try to sell within the
Territory, any lines or products that, in Supplier's judgment, compete with the
Products covered by this Agreement. As of the date of the signing of this
contract, the Supplier has reviewed the product lines of the Distributor and
they have been deemed to be non-competitive with the Supplier's product line.
e. That Distributor will sell the quota of Product specified in
Attachment C during the periods specified therein. If Distributor fails during
any period specified in Attachment C to sell the quota of Product for that
period, Supplier shall have the right to notify Distributor of default and give
such thirty (30) days notice of such default, and Distributor shall then have an
additional ninety (90) days to cure such default. If default is cured, then
contract shall revert to its prior amicable status. Should Distributor continue
to be in default after the total 120-day period, Supplier may either convert
contract to non-exclusive, or at its option, terminate contract per Paragraph
11, Section c.
f. To ascertain and comply with, at Distributor's sole expense, all
applicable laws and regulations and standards of industry or professional
conduct, including without limitation, those applicable to product claims,
labels, instructions, packaging or the like.
g. To use best efforts, at its sole expense, to obtain and maintain
any applicable approvals, registrations, notifications or the like with regard
to marketing, using, selling, labeling or otherwise promoting or making claims
regarding the Products or their uses or reimbursement therefor in the Territory.
Distributor shall not file any such application or document or conduct any study
without Supplier's prior written consent, which shall not be unreasonably
withheld. To the extent allowed by law all approvals, registrations,
notifications and the like (and all documents, applications and information
related thereto) and all rights thereunder or thereto shall be for the sole
benefit of and shall be solely owned by and in the name of Supplier.
Distributor will provide Supplier with any information regarding the foregoing
that Supplier may request. Supplier may use such information in its discretion.
h. To immediately notify Supplier of any adverse or unexpected
results or any actual or potential government action relevant to a Product and,
if and to the extent requested by Supplier in writing, to suspend distribution
of that Product.
3
<PAGE>
i. To keep for five years after expiration or termination of this
Agreement records of all Product sales and customers sufficient to adequately
administer a recall of any Product and to fully cooperate in any decision by
Supplier to recall, retrieve and/or replace any Product.
j. To keep Supplier informed as to any problems encountered with the
Products and any resolutions arrived at for those problems, and to communicate
promptly to Supplier any and all modifications, design changes or improvements
of the Products suggested by any customer, employee or agent. Distributor
further agrees that Supplier shall have any and all right, title and interest in
and to any such suggested modifications, design changes or improvements of the
Products, without the payment of any additional consideration therefor either to
Distributor, or its employees, agents or customers. Distributor will also
promptly notify Supplier of any infringement of any trademarks or other
proprietary rights relating to the Products.
5. COMPLIANCE WITH LAWS.
a. Without limitation of the foregoing, Distributor agrees to commit
no act which, directly or indirectly, would violate any United States federal or
state laws or regulation relating to or applicable to the sale of the Products.
Without limitation, Distributor will not remove or export from the United States
or re-export from anywhere any Product or component thereof to Afghanistan, the
People's Republic of China or any Group Q, S, W, Y or Z country (as specified
from time to time in Supplement No. 1 to Section 770 of the U.S. Export
Administration Regulations, or a successor thereof) or otherwise except with and
in compliance with all licenses and approvals required under all applicable
export laws and regulations, including without limitation, those of the U.S.
Department of Commerce.
b. Distributor agrees to indemnify, defend and hold harmless
Supplier from any and all fines, damages, losses, costs and expenses (including
reasonable attorneys' fees) incurred by Supplier as a result of the breach of
this Section 5 by Distributor.
6. CONFIDENTIALITY. Distributor agrees that all inventions, know-how and
ideas it obtains from Supplier and all other business, technical and financial
information it obtains from Supplier are the confidential property of Supplier
("Proprietary Information"). Except as expressly and unambiguously allowed
herein, Distributor will hold in confidence and not use or disclose any
Proprietary Information to Distributor's employees or others. Distributor's
nondisclosure obligation shall not apply to information it can document has
entered the public domain and is generally available to the public. Distributor
will promptly report to Supplier any actual or suspected violation of the terms
of this Section 6, and will take all reasonable further steps requested by
Supplier to prevent, control or remedy any such violation. Distributor shall,
upon the termination of the Agreement or the request of Supplier at any time,
return to Supplier all tangible manifestations of confidential information
received by Distributor pursuant to this Agreement (and all copies and
reproductions thereof).
7. WARRANTY AND DISCLAIMER. Supplier warrants to Distributor and
customer that the Products will be free from manufacturing and material defects
for twelve (12) months after delivery to customer. Products purchased from
Supplier which do not comply with the warranty and are returned by Distributor
or customer to Supplier during such period (with proof of the date of purchase)
will be repaired or replaced. If proven to be a manufacturing defect, Supplier
will pay freight. If problem is the cause of customer or Distributor, then
customer or Distributor will pay freight. Distributor or customer must return
any such Products to Supplier and shall conspicuously bear the Return Material
Authorization (RMA) number Distributor obtains from Supplier prior to
4
<PAGE>
return. If supplier cannot, or determines that is not practical to, repair or
replace the returned Product, the purchase price therefore will be refunded.
SUPPLIER MAKES NO OTHER WARRANTIES WITH RESPECT TO THE PRODUCTS OR ANY SERVICES
AND DISCLAIMS ALL OTHER WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. The above warranty does
not extend to any Product that is modified or altered, is not maintained to
Supplier's maintenance recommendations, is operated, handled or stored in a
manner other than that specified by Supplier, has its serial number removed or
altered or is treated with abuse, negligence or other improper treatment
(including, without limitation, use outside the recommended environment).
Distributor's sole remedy with respect to any warranty or defect is as stated
above.
8. LIMITED LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR
OTHERWISE, SUPPLIER WILL NOT BE LIABLE UNDER ANY SECTION OF THIS AGREEMENT, OR
UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE
THEORY, (A) FOR ANY AMOUNTS IN EXCESS IN THE AGGREGATE OF THE AMOUNTS PAID TO
SUPPLIER HEREUNDER DURING THE TWELVE MONTH PERIOD PRIOR TO DATE THE CAUSE OF
ACTION AROSE OR (B) FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, (C) FOR COST
OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, OR (D) DAMAGES
ARISING FROM THE LOSS OF PROFITS OR LOSS OF BUSINESS. SUPPLIER SHALL HAVE NO
LIABILITY FOR ANY FAILURE OR DELAY DUE TO MATTERS BEYOND ITS REASONABLE CONTROL.
9. RELATIONSHIP OF PARTIES/HOLD HARMLESS AND INDEMNIFICATION. The
parties hereto expressly understand and agree that Distributor is an independent
contractor in the performance of each and every part of this Agreement, is not
an agent, and is solely responsible for all its employees and agents and its
labor costs and expenses arising in connection therewith and:
a. The Distributor and Supplier shall indemnify and save each other
harmless from all loss, damage, cost or expense of any nature, arising from or
in any way connected with any injury to persons or property caused by or
resulting from any act of negligence of the other, or its agents, in the use of
the Products.
b. Supplier shall indemnify and hold Distributor harmless from and
against all claims, demands and proceedings, arising out of any claims under
Supplier's warranty or arising out of any allegation that any manufacturing or
design defect, whether or not arising out of Supplier's negligence, exists with
regard to the Products and such defect has caused damage to the other party or
any other third party.
c. A party seeking indemnification under this Agreement (an
"indemnified party") shall give notice to the party from whom such
indemnification is sought ("indemnifying party") within thirty (30) days of the
assertion of any claim (including discovery of any loss, damage or injury giving
rise to any claim by the indemnified party), or the commencement of any action,
suit, or proceeding, in respect of which indemnity may be sought hereunder.
Provided, however, the obligation of the indemnified party to give notice to the
indemnifying party shall not arise until the later to occur of: (i) the
assertion of a claim or commencement of an action, or (ii) the receipt by the
indemnified party of notice of claim or service of court process with regard to
such proceeding. Failure to give such notice shall relieve the indemnifying
party of any liability hereunder. The indemnified party shall give the
indemnifying party such information regarding the claim, action or proceeding as
the indemnifying party may reasonably request. If a claim for indemnification
arises
5
<PAGE>
from any action, suit or proceeding, the indemnifying party shall, at its
expense assume the defense of such action, suit or proceeding. In such case the
indemnified party shall have the right, but not the duty, to participate in its
own defense and to employ at its own expense counsel separate from counsel
employed by the indemnifying party; provided, however, if a conflict exists in
conducting the defense of the parties on a joint basis, the indemnifying party
will be responsible for the expenses and fees of separate counsel for the
indemnified party. The indemnifying party shall be liable for the fees and
expenses of counsel employed by the indemnified party if the indemnifying party
has not assumed the defense thereof. Whether or not the indemnifying party
chooses to defend or prosecute any claim, all the parties hereto shall cooperate
in the defense or prosecution thereof and shall furnish such records,
information and testimony, and attend such conferences, discovery proceedings,
hearings, trials and appeals, as may reasonably be requested therewith. The
indemnifying party shall not be liable under this subparagraph (b) for any
settlement effective without its consent, which consent shall not be
unreasonably withheld.
Except as expressly provided herein, Supplier shall have no right to
exercise any control whatsoever over the activities or operations of
Distributor.
10. ASSIGNMENT. This Agreement and the rights hereunder are not
transferable or assignable by a party without the prior written consent of the
other party, except for rights to payment and except to a person or entity who
acquires all or substantially all of the assets or business of Supplier, whether
by sale, merger or otherwise. Distributor will have the right to assign
agreement with Supplier's written consent, which will not be unreasonably
withheld.
11. TERM AND TERMINATION. Unless terminated earlier as provided herein,
this Agreement shall have a term extending from the date of this Agreement to
December 31, 2001. This Agreement is renewable for one year extensions with the
written consent of each party delivered to the other within sixty (60) days
before expiration of this Agreement. Distributor understands that after the
date specified above or earlier termination, it shall have no right whatsoever
to purchase Products or continue as a dealer or distributor or otherwise
regardless of any undocumented continuation of the relationship with Supplier.
a. This Agreement may be terminated by a party for cause other than
for performance pursuant to Paragraph 11, Section (c) with thirty (30) days
written notice upon the occurrence of any of the following events:
i. If the other ceases to do business, or otherwise terminates
its business operations; or
ii. If the other shall fail to secure or renew any license,
registration, permit, authorization or approval for the conduct of its business
in the manner contemplated by this Agreement or if any such license,
registration, permit, authorization or approval is revoked or suspended; or
iii. Except as set forth below in Paragraph 11, Section (c), if
the other breaches any provision of this Agreement other than performance as
stipulated, and fails to fully cure such breach within thirty (30) days [ten
(10) days in the case of a failure to pay] of written notice describing the
breach; or
iv. If the other seeks protection under any bankruptcy,
receivership, trust deed, creditors arrangement, composition or comparable
proceeding, or if any such proceeding is instituted against the other.
b. Supplier may immediately terminate this Agreement for no cause
upon (two) years written notice if Distributor or Distributor's assets or
business is acquired by a third party ("acquired
6
<PAGE>
for purposes of this provision means that the third party has obtained 50% or
more of the capital shares or voting power). Additionally, the Supplier may
terminate this Agreement upon two years written notice if Supplier or Suppliers'
assets or business is acquired by a third party. "Acquired" for purposes of this
provision means that the third party has obtained 50% or more of the capital
shares or voting power.
c. Supplier shall have the right to terminate this Agreement as set
forth herein, in the event of Distributor's failure to meet its quota
obligations specified in Attachment C ("Quota Violation"). Supplier shall have
the right, upon the occurrence of a Quota Violation, to give the Distributor
thirty (30) days written notice of the Quota Violation (the "Notice Period").
Distributor shall have the right to cure the Quota Violation during the Notice
Period and for an additional ninety (90) day period after the expiration of the
Notice Period (the "Cure Period"). In the event that the Distributor cures the
Quota Violation prior to the expiration of the Cure Period, the notice of Quota
Violation shall be null and void and this Agreement shall return to its prior
status. In the event that the Distributor does not cure the Quota Violation
prior to the expiration of the Cure Period, this Agreement may be terminated by
the Supplier in its sole discretion, by written notice to the Distributor.
d. Either party shall have the right to terminate this Agreement for
no cause upon ninety (90) days written notice to the other. (The date upon
which the ninety day period expires shall be the "Termination Date.") In the
event that Supplier elects to terminate this Agreement pursuant to this
Paragraph (d), then, upon such termination or expiration of Agreement, the
Supplier shall pay to the Distributor an amount equal to the lessor of (a) Five
Hundred Thousand Dollars ($500,000); or (b):
i. Nine (9) times the Termination Amount (as hereinafter
defined) if the termination occurs between March 27, 1997 and January 1, 2001.
As used herein, the Termination Amount shall be equal to fifteen percent
(15%) of the Distributor's average monthly gross sales of the Products for the
monthly average of the three (3) complete months immediately preceding the Date
of Notice of Termination.
e. In the event of expiration or any termination, Supplier may elect
to continue or terminate any purchase order then pending.
f. In addition to any provisions that survive expiration or
termination according to their terms and any restrictions on Distributor's
distribution of Products, the following sections shall survive termination of
this Agreement: Sections 3 a, c, e, f, g; and Paragraphs 4 through 9.
g. Upon expiration or termination, if Distributor has any right,
title or interest in any Mark (as defined in Paragraph 3.b) or any registration
related thereto or in anything referred to in Section 3.h, it will immediately
assign all such right, title and interest to Supplier and take all necessary
action to ensure that Supplier obtains the full benefit thereof or, if Supplier
so requests in writing with respect to any such item, take any necessary action
to surrender and cancel such item and the related rights, title and interest.
h. Termination is not the sole remedy under this Agreement and,
whether or not termination is effected, all other remedies will remain
available.
i. Upon termination or expiration of Agreement, Distributor can
return any unsold inventory stock that has been purchased within the last twelve
(12) months, and/or demo equipment. Unsold new inventory can be returned to
Supplier for the purchase price paid by the Distributor. Supplier will pay
Distributor for returned demo equipment the purchase price of equipment less 5%
for the first ten (10) months of life, and an additional 2% per month over the
initial ten (10) months.
7
<PAGE>
12. DUTIES OF DISTRIBUTOR UPON TERMINATION. Upon the termination of this
Agreement for any reason whatsoever, Distributor shall:
a. Pay to Supplier, in full within forty-five (45) days of such
termination, all amounts owed to Supplier. Supplier shall be entitled to set
off and deduct from any money due Distributor or vice versa, whether or not
arising under this Agreement, any and all amounts due Supplier from Distributor,
or vice versa, unless there is a dispute. Such dispute shall be settled by
arbitration per Paragraph 13, Section (f).
b. Promptly return to Supplier any and all Supplier-owned Product or
other materials, documentation or data, including without limitation all
promotional material, in the possession of Distributor for whatever reason or
purpose, such Product, material, documentation and data to be in the same
condition as when delivered to Distributor.
c. Cooperate with Supplier in completing all outstanding obligations
to Distributor's customers.
d. Within thirty (30) days after notice of termination or expiration
of Agreement by either Distributor or Supplier, prepare a statement listing all
active and prospective customers and the type and amount of orders of Product
expected to be sold to such customers by Distributor during the sixty (60) day
period following the date of termination or expiration of this Agreement.
Distributor shall also deliver to Supplier within such thirty (30) day period
all orders for Product received by Distributor after the date of the notice of
termination or expiration. Supplier shall fill all such orders on behalf of
Distributor, subject to Supplier's approval of the terms, conditions, credit
worthiness and pricing of any such orders, and shall pay to Distributor a
commission equal to thirty percent (30%) of the sales price for Product sold
pursuant to such orders, within thirty (30) days after receipt of payment
therefor.
13. GENERAL.
a. Amendment and Waiver - Except as otherwise expressly provided
herein, any provision of this Agreement may be amended and the observance of any
provision of this Agreement may be waived (either generally or any particular
instance and either retroactively or prospectively) only with the written
consent of the parties. However, it is the intention of the parties that this
Agreement be controlling over additional or different terms of any purchase
order, confirmation, invoice or similar document, even if accepted in writing by
both parties, and that waivers and amendments shall be effective only if made by
non-preprinted agreements clearly understood by both parties to be an amendment
or waiver.
b. Governing Law and Legal Actions - This Agreement shall be
construed, interpreted, administered and governed in accordance with the laws of
the State of California. In any action or proceeding to enforce rights under
this Agreement, the prevailing party shall be entitled to recover reasonable
costs and reasonable attorney's fees.
c. Headings - Headings and captions are for convenience only and are
not to be used in the interpretation of this Agreement.
d. Notices - For purposes of this Agreement, and for all notices and
correspondence hereunder, the addresses of the respective parties have been set
out at the beginning of this Agreement, and no change of address shall be
binding upon the other party hereto until written notice thereof is received by
such party at the address shown herein. All notices shall be deemed received
when personally delivered or two (2) days after being sent by overnight
courier, return receipt requested.
e. Entire Agreement - This Agreement is the parties' entire
agreement and supersedes all proposals, oral or written, and all arrangements,
understandings, negotiations, conversations or
8
<PAGE>
discussions between the parties relating to the subject matter of this Agreement
and all past dealing or industry custom. This Agreement does not contain or
constitute any express or implied license to make, have made or modify any
Product under any circumstances.
f. Termination Disputes - Disputes arising from the process of
termination, that are not determined by this contract which are not
satisfactorily negotiated by each party within thirty (30) days of the Effective
Date of termination, shall be submitted to the American Arbitration Association
for a binding arbitration. Supplier and Distributor agree that this Association
shall use a panel of three (3) arbitrators to review the matter in question and
the majority of said arbitrators shall determine the questions in accordance
with the AAA's commercial arbitration rules, and in accordance with then
existing law of California; said arbitration to take place in Denver, Colorado.
g. Insurance - The Supplier shall maintain insurance coverage issued
by a responsible insurer in the amount of at least One Million Dollars
($1,000,000). Said coverage shall name the Distributor as an additional insured
and shall have a vendor endorsement satisfactory to Distributor covering
Distributor. The Supplier shall, from time to time, and upon the request of the
Distributor, provide the Distributor with a certificate of insurance from the
insurer certifying that the Supplier has complied with the provisions of this
paragraph. The Supplier shall not cancel the insurance coverage, remove
Distributor as an additional insured or alter the vendor endorsement, except
upon thirty (30) days prior written notice to the Distributor. Supplier shall
then have sixty (60) days to cure such default. Should Supplier continue to be
in default upon the expiration of the sixty (60) day period, Distributor shall
have the right to terminate this Agreement and shall receive the amounts set
forth in Paragraph 11, Section (d), as if the Supplier had terminated this
Agreement without cause.
h. Severability - All provisions contained herein are severable and
in the event that any of them shall be held to be to any extent invalid or
otherwise unenforceable by any court of competent jurisdiction, such provision
shall be construed as if it were written so as to effectuate to the greatest
possible extent of the parties' expressed intent; and in every case the
remainder of this Agreement shall not be affected thereby and shall remain valid
and enforceable, as if such affected provision were not contained herein.
SUPPLIER:
CardioDynamics International Corporation
A California Corporation
By: /s/ Richard E. Otto
-------------------------------
Richard E. Otto
President/CEO
DISTRIBUTOR:
Kol Bio Medical Instruments, Inc.
A Virginia Corporation
By: /s/ Roger S. Kolasinski
-------------------------------
Roger S. Kolasinski
President
9
<PAGE>
ATTACHMENT A
TERRITORY
Territory is to consist of North Carolina; South Carolina; Georgia* (excluding
South Georgia); Maryland; Washington, DC; Virginia.
* The excluded territory of Georgia is comprised of the following counties and
all territory South: Clay, Calhoun, Dougherty, Worth, Tift, Irwin, Douglas,
Bacon, Pierce, Brantly, and Glynn.
10
<PAGE>
ATTACHMENT B
Products and Hospital Distributor Wholesale Price List
In Effect on the Date of the Agreement
All price quotas are prepaid F.O.B. Supplier's applicable warehouse or place of
production.
11
<PAGE>
ATTACHMENT C
Sales Quota
Sales quotas for each calendar year of the contract will be mutually agreed upon
by CardioDynamics International Corporation (CDIc) and Kol Bio Medical
Instruments, Inc. This quota will be determined by November 1, of the year
preceding the forecasted year. The quota will be based on several factors
including U.S. sales, population of designated territory and expected sales
growth rates. CDIc's Director of Sales may require the forecast and quota to be
done on a state-by-state basis.
For 1997, the following is the agreed upon sales quotas:
Product Number of Units
------- ---------------
BioZ Systems 15 monitoring systems
Transducer Electrodes 1500 patient applications
Electrode number based on 15 units being active for one third (1/3) of the time:
fifteen (15) x twenty-five (25) electrodes/month/BioZ System x four (4) months =
1500 applications).
The Supplier will also consider the Distributor as achieving sales quota if
Distributor's sales equal fifteen percent (15%) or more of Supplier's total U.S.
sales.
12
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM QUARTER
ENDED MAY 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> NOV-30-1997
<PERIOD-START> MAR-01-1997
<PERIOD-END> MAY-31-1997
<CASH> 4,701,109
<SECURITIES> 0
<RECEIVABLES> 552,473
<ALLOWANCES> 5,632
<INVENTORY> 690,989
<CURRENT-ASSETS> 5,949,105
<PP&E> 349,508
<DEPRECIATION> 179,426
<TOTAL-ASSETS> 6,125,689
<CURRENT-LIABILITIES> 381,787
<BONDS> 0
0
457,791
<COMMON> 14,323,569
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 6,125,689
<SALES> 778,528
<TOTAL-REVENUES> 778,528
<CGS> 367,420
<TOTAL-COSTS> 985,716
<OTHER-EXPENSES> (71,746)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (502,862)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (502,862)
<EPS-PRIMARY> (0.02)
<EPS-DILUTED> (0.02)
</TABLE>
